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Zusammenfassung 
 
In der medizinischen Forschung wird große Hoffnung in embryonale Stammzellen und 
induzierte pluripotente Stammzellen gesetzt. Dies liegt vor allem an ihren besonderen 
Eigenschaften, wie die Fähigkeit sich zum Einen unbegrenzt selbsterneuern zu können 
sowie zum Anderen in Zellen aller drei Keimblätter differenzieren zu können. Daher 
stellen embryonale und induzierte pluripotente Stammzellen eine potentielle Grundlage 
in der Regenerativen Medizin in Form von Zellersatztherapien und Gewebezüchtung. 
Bevor diese möglichen Therapiestrategien allerdings Eingang in die klinische Versor-
gung von Patienten finden, ist zunächst von besonderer Bedeutung das komplexe re-
gulatorische Netzwerk, das Pluripotenz und Selbsterneuerung in embryonalen 
Stammzellen ermöglicht, zu entschlüsseln und zu verstehen. 
In diesem Zusammenhang erfährt der Transkriptionsfaktor B-Myb besondere Aufmerk-
samkeit, weil er in der Aufrechterhaltung von Pluripotenz, normaler Abfolge des 
Zellzyklus und chromosomaler Stabilität eine wichtige Rolle spielt. Da B-Myb die 
Expression von einigen Proteinen reguliert, die entweder mit dem Zellzyklus oder der 
Differenzierung von embryonalen Stammzellen in Verbindung gebracht werden, ergab 
sich die Fragestellung, ob einzelne dieser Zielgene eine Schlüsselfunktion ausüben oder 
ob B-Myb durch die Interaktion von mehreren Proteinen seine Funktion erfüllt. Aufgrund 
von vorangehenden Versuchen in somatischen Zellen, wurden die beiden Zielgene 
Aurora Kinase A und Cyclin B1 ausgewählt, um herauszufinden, ob sie in besonderer 
Weise zu der Funktion von B-Myb beitragen. 
Im Rahmen meiner Doktorarbeit wurden Aurora Kinase A und Cyclin B1 mithilfe von 
microRNAs in embryonalen Stammzellen herunterreguliert und der Zellzyklus sowie der 
Spindelapparat während der Mitose untersucht. Besonderes Augenmerk lag darauf, ob 
der Phänotyp, der in früheren Experimenten durch Ausschaltung von B-Myb beobachtet 
wurde, durch Herunterregulierung eines der beiden Zeilgene nachgeahmt werden 
konnte. Im Gegensatz zu Ergebnissen aus somatischen Zellen führte ein partielles 
Ausschalten von Aurora Kinase A und Cyclin B1 in embryonalen Stammzellen allerdings 
nicht zu einem abnormen Zellzyklus oder Veränderungen während der Mitose. Der 
Phänotyp, der durch Abschalten von B-Myb erzielt wurde, konnte durch ein teilweises 
Herunterregulieren von Aurora Kinase A oder Cyclin B1 nicht reproduziert werden.  
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Demnach sind entweder mehrere Proteine für die Funktion des Transkriptionsfaktor B-
Myb verantwortlich oder ein spezielles Zielgen, das bisher noch nicht untersucht wurde.  
Weitere Zielgene können in analoger Weise wie Aurora Kinase A und Cyclin B1 oder 
mithilfe der Ainv15 Zelllinie untersucht werden. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7 
 
List of Abbreviations 
Aurka -  Aurora Kinase A 
bp    -  base pair(s) 
Ccnb1 -  Cyclin B1 
cdk    -  cyclin dependent kinase 
ChIP    -  chromatin immunoprecipitation 
CMV    -  Cytomegalovirus   
Dapi -  4′,6-Diamidin-2-phenylindole 
dsRNA -  double-stranded RNA 
DTT -  Dithiothreitol 
EDTA -  Ethylenediaminetetraacetic acid 
(Em)GFP   -   (Emerald) Green Fluorescent Protein 
ES cell   -   embryonic stem cell 
G1/G2-phase  -  gap1/gap2 phase 
GAPDH  -  Glyceraldehyde-3-phosphate dehydrogenase  
GTP  -  Guanosine-5'-triphosphate 
h -  hour 
hES cell   -  human embryonic stem cell 
HMG    -  high mobility group 
Hprt    -  hypoxanthine-guanine phosphoribosyl- 
transferase          
HRP  -  horse radish peroxidase 
ICM    -  inner cell mass 
IgG -  Immunglobulin G 
iPS cell   -  induced pluripotent stem cell 
Kb -  kilo base-pairs 
LB medium -  Lysogeny broth medium 
LIF -  Leukemia inhibitory factor 
LINC    -  linker of nucleoskeleton and cytoskeleton 
M-phase   -  mitosis phase 
mES cell   -  mouse embryonic stem cell  
miR, miRNA   -  microRNA  
8 
 
PBS -  Phosphate Buffered Saline 
(p)RB -  (phosphorylated) Retinoblastoma protein  
Pre-miRNA -  precursor-microRNA  
Pri-miRNA -  primary-microRNA 
PVDF -  Polyvinylidene Fluoride 
R point   -  restriction point 
Ripa buffer -  Radioimmunoprecipitation assay buffer 
RISC  -  RNA-induced silencing complex 
RNAi    -  RNA interference 
rtTA    -  reverse tetracycline transactivator 
S-phase -   synthesis phase 
SDS -  sodium dodecyl sulfate 
shRNA -  short hairpin RNA 
TBE  -  Tris-Borate EDTA  
TE -  Tris-EDTA 
TRE     -  tetracycline responsive element  
 
 
 
 
 
 
 
 
 
9 
 
1. Introduction  
1.1       Embryonic Stem Cells 
1.1.1                      Brief overview 
Embryonic stem cells were first derived from mouse embryos in 1981 by two indepen-
dent research groups (Evans & Kaufman, University of Cambridge, and Martin, Univer-
sity of California). These pluripotent cells are derived from the inner cell mass (ICM) of 
preimplantation embryos and give rise to all cell types evolved from the three primary 
germ layers, when differentiated in vitro (Evans and Kaufman, 1981; Martin, 1981; 
Thomson et al., 1998). Seventeen years after these initial discoveries, Thomson et al. 
(University of Wisconsin-Madison) established a breakthrough in human biomedical 
research by isolating embryonic stem cells from human blastocysts. Since this 
milestone, embryonic stem cells, with their unlimited self-renewal capacity and the ability 
to differentiate into all types of cells, have been hailed as a boon for regenerative 
medicine. This is because ES cells represent an experimental model system for the 
study of early mammalian and human development (Martin, 1981), and can function as 
a resource for in vitro screenings of pharmaceutical products and for toxicology studies. 
Most importantly, embryonic stem cells and their derivatives may serve as a possible 
source for cell replacement therapies that have the capacity to treat injuries and 
degenerative diseases such as heart failure, parkinsonism, diabetes or amyotrophic 
lateral sclerosis (Pera and Trounson, 2004; Stojkovic et al., 2004; Thomson et al., 1998). 
Several problems must however be overcome before the goal of clinical applications can 
be realized. These include an understanding of how to efficiently direct and control dif-
ferentiation into specific cell lineages in vitro. Moreover, problems of tumor formation or 
immunological rejection must also be overcome (Boheler, 2009). For this, ES cells may 
need to be fully differentiated into the desired cell type and residual pluripotent undiffer-
entiated cells may need to be removed completely. Immunological rejection may also be 
obviated through the use of induced pluripotent stem (iPS) cells, which are largely indis-
tinguishable from blastocyst-derived ES cells (Boheler, 2009). IPS cells can be prepared 
in vitro by transcription factor (mouse: Oct4/ Sox2/ c-Myc/ Klf4; human: Oct4/ Sox2/ 
Nanog/ LIN28) reprogramming of adult somatic cells isolated directly from the patient 
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(Takahashi et al., 2007; Takahashi and Yamanaka, 2006). Since these cells are isolated 
from the patient, iPS cell derivatives should be immunologically compatible with the host. 
Finally and before achieving the goal of therapeutics, a more thorough understanding of 
the molecular mechanisms that form the basis of the pluripotent state of embryonic stem 
and induced pluripotent stem cells is required. In this regard it is important to unravel the 
interaction and regulatory network of pluripotency factors, transcription factors, cell cycle 
regulation and their target genes in ES cells. Towards this goal, my thesis deals with the 
role of B-Myb, an important transcription factor in embryonic stem cells, and its target 
genes Aurora Kinase A and Cyclin B1 in ES cells. 
 
1.1.2                      Pluripotency factors  
At least three transcription factors, OCT4, SOX2 and NANOG, play critical roles in early 
mammalian development and are required for the maintenance of self-renewal and pluri-
potency (Boyer et al., 2005; Loh et al., 2006).  
OCT 4, encoded by the gene pou5f1, belongs to a POU transcription factor family and is 
expressed in the inner cell mass (ICM) as well as in the epiblast (Chen et al., 2008). 
Appropriate levels of OCT4 are critical to maintain pluripotency in ES cells, because a 
greater than twofold increase causes differentiation into primitive endoderm and meso-
derm, while a significant reduction leads to differentiation into trophoectoderm (Niwa et 
al., 1998). The transcription factor SOX2 contains a single HMG (high mobility group) 
DNA binding domain and is expressed in ES cells in a similar manner as OCT4 (Chen et 
al., 2008).  SOX2 also heterodimerizes with OCT4 to regulate gene expression (Botquin 
et al., 1998). Last but not least the core regulator NANOG, a homeodomain containing 
protein, is expressed in the ICM and the epiblast. Additionally NANOG overexpression 
enables mouse ES (mES) cells to grow in culture without the Leukemia Inhibitor Factor 
(LIF), which is normally required to maintain self-renewal. Moreover, as OCT4 inhibits 
the formation of trophoectoderm it appears that NANOG inhibits differentiation into prim-
itive endoderm (Boheler, 2009).  
Besides OCT4, SOX2 and NANOG, which are all highly expressed in the inner cell mass 
of developing embryos, several other transcription factors are associated with ES cell 
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pluripotency, including but not limited to, c-Myc (Cartwright et al., 2005), Sall4 (Zhang et 
al.,2006), Tbx3 (Ogawa et al., 2007) and Zic3 (Lim et al., 2007). Like OCT4, SOX2 and 
NANOG, these are expressed in the ICM of blastocysts and often show decreased ex-
pression upon differentiation.  
 
Moreover, the three principal pluripotency regulators co-occupy the promotors of at least 
353 genes in hES cells (Boyer et al., 2005). Since OCT4, NANOG and SOX2 bind to 
DNA sequences, which are at times located within 25 bp of one another, the data sug-
gest that they form tightly associated complexes (Marson et al., 2008). Importantly, they 
not only occupy target genes, these factors actually regulate them, which results in ei-
ther gene activation or repression. Among the actively transcribed target genes are 
several transcription factors, known pluripotency regulators (Boheler, 2009), as well as 
components of signaling pathways that are involved in pluripotency and self-renewal. 
Repressed genes that bind these pluripotency regulators mostly encode transcription 
factors implicated in developmental processes (Boyer et al., 2005). OCT4, NANOG and 
SOX2 thus provide a regulatory network that consists of autoregulatory and feedforward 
loops (Boyer et al., 2005; Loh et al., 2006). Binding to the promotors of their own genes 
results in interconnected autoregulatory loops that confer several advantages. On the 
one hand gene expression becomes more stable, while on the other hand the regulatory 
network is capable of responding more rapidly to external signals.  
The feedforward mechanism is based on a regulator that controls a second regulator, 
and both share a set of common target genes. In this case OCT4, SOX2 and NANOG 
act as those key regulators, which co-occupy and control a large set of genes encoding 
many other transcriptional regulators expressed in ES cells. The control of these sec-
ondary regulators leads to a hierarchical regulatory network structure that allows a rapid 
change in gene expression due to the fact that only three key regulators need to be tar-
geted (Boyer et al., 2005; Cole and Young, 2008). 
In conclusion this regulatory network enables ES cells to robustly maintain pluripotency 
and self-renewal, while being competent to respond appropriately to differentiation 
signals.  
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Figure 1: Transcriptional Regulatory Motifs in Embryonic Stem Cells 
(A) Interconnected autoregulatory loop provided by OCT4, SOX2 and NANOG in ES cells. 
The green rectangles represent promoters and the blue circles represent regulators. 
Solid arrows indicate binding of a regulator to a promoter and dashed arrows connect 
genes encoding regulators and their respective regulators. 
(B) Feedforward loop formed by OCT4, SOX2 and NANOG. 
 
 
1.1.3                      ES cell cycle   
ES cells have a unique cell cycle that differs in total length, duration of the individual 
phases and cell cycle regulation when compared to differentiated somatic cells. The un-
usual rapid rate of cell division takes approximately 8-10 h in mES and 15-16 h in hES 
cells (vs. ~24-32 h in most actively proliferating somatic cells) (Becker et al., 2006; Stead 
et al., 2002). This extremely short generation time is achieved for the most part by 
shortening of the G1 phase, so that the cell cycle is composed mainly of DNA replication 
(S phase) and chromosome segregation (M phase) (Becker et al., 2006; Stead et al., 
2002; White and Dalton, 2005). On the contrary, most somatic cell types stay typically in 
the main in G1, and need to be activated to pass the restriction (R) point in order to un-
dergo a new round of cell division. This R checkpoint is also known as the ‘point of no 
return’, because once a cell has passed this, it will run through the cell cycle growth 
factor independently.  
The molecular machinery required for cell cycle progression consists of a catalytic sub-
unit, the cyclin-dependent protein kinases (Cdks), and a regulatory element, the cyclins 
(White and Dalton, 2005). These cyclins are unstable proteins, which are synthesized 
and degraded at different stages throughout the cell cycle. Since forming a complex with 
the correspondent Cdk leads to activation, the cell cycle contains periodic changes of 
phase-specific catalytic functions of Cdks. Normally Cdk4/6-cyclin D and Cdk2-cyclin E 
are activated in somatic cells to provide the transition from G1 to S phase (Stead et al., 
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2002). In this connection the pRB-E2F pathway plays another decisive role due to the 
fact that phosphorylation of pRB by Cdk activity leads to derepression of E2F target 
genes in G1, which are required for DNA replication in S phase (White and Dalton, 
2005). 
By contrast, embryonic stem cells are characterized by a shortened G1 phase that lacks 
the normal restriction point (Stead et al., 2002). Furthermore they have a precocious ac-
tivity of Cdks without the typical cell cycle dependent periodicity (Faast et al., 2004; 
Stead et al., 2002). Namely, except for the Cdk1-cyclin B complex, all cyclins (A, D, E) 
expressed in ES cells show comparable amounts throughout the whole cell cycle 
(Becker et al., 2006; Faast et al., 2004; Stead et al., 2002). The fact that cyclins have 
significantly elevated levels during the entire ES cell cycle compared to somatic cells as 
well as the constant activity of Cdks is responsible for their rapid rate of cell division 
(Becker et al., 2006; Stead et al., 2002; White and Dalton, 2005). 
Additionally, the constitutive activation of these kinases holds pRB and p107 in a hyper-
phosphorylated state, which inactivates the pRB-E2F pathway (Savatier et al., 1994), so 
that their target genes, such as the important transcription factor B-Myb, are transcribed 
cell cycle independently (Stead et al., 2002). Since ES cells do not have the pRB/E2F 
switch that normally takes place at the R point and supports commitment to S phase en-
try, their cell cycle progression is independent of external factors e.g. exogenous growth 
factors or contact inhibition (Becker et al., 2010; White and Dalton, 2005). Recent 
studies have pointed out that, due to the lack of an E2F/pRB switch, hES cells are al-
ready determined in mitosis to run through the next S phase without the requirement of 
external regulatory signals (Becker et al., 2010). Furthermore, hES cells create a special 
medium by secreting autocrine factors in order to maintain their abbreviated G1 phase 
(Becker et al., 2010). 
Differentiation of ES cells leads to an essential change in cell cycle regulation and 
structure, so that they show the characteristics normally seen in other mammalian cells.  
At some point Cdk activity changes and becomes highly regulated as well as cell cycle 
dependent afterwards. In addition, the pRb/E2F pathway becomes activated, and 
therefore the restriction point is established. These changes yield to fully developed G1 
and G2 phases, which are typically for differentiated somatic cells (White and Dalton, 
2005). 
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Since the change in cell cycle regulation upon differentiation happens prior to the de-
crease in OCT4, NANOG and SOX2 protein abundance, provides support for the fact 
that the lack of cell cycle checkpoints is linked to the ability of maintaining pluripotency 
(Boheler et al., 2009). 
In conclusion, these alterations connected to differentiation demonstrate that loss of G1 
functions as well as precocious cell cycle regulatory mechanism are tightly linked to 
pluripotency and self-renewal (Becker et al., 2010; White and Dalton, 2005). 
  
1.1.4                      Epigenetic state  
Multiple regulatory mechanisms are involved in the maintenance of the undifferentiated 
state of ES cells. On the one hand, binding of transcription factors plays an important 
role as previously mentioned. On the other hand, epigenetic factors such as DNA 
methylation or chromatin structure are connected with pluripotency and the initiation of 
differentiation (Bibikova et al., 2008). 
The three different epigenetic states are euchromatin, constitutive heterochromatin and 
facultative heterochromatin.  
Euchromatin contains the actively transcribed genes, whereas facultative heterochroma-
tin is the result of gene silencing, but can again become transcriptionally active under 
specific circumstances. By contrast, constitutive heterochromatin is usually repetitive 
DNA that is highly condensed and supposed to be gene poor. In consequence of their 
different transcriptional activity, all three states vary in levels of DNA methylation, his-
tone modification and timing of replication in S phase (Arney and Fisher, 2004). 
Since embryonic stem cells differentiate without detectable changes in the DNA 
sequence, epigenetic factors are implicated in activation and inactivation of particular 
sets of genes. Cell differentiation is associated with methylation and demethylation of 
genomic DNA in order to establish a required formation of tissue-specific patterns of 
gene expression (Li, 2002; Shiota et al., 2002). Accordingly, the genes of the 
pluripotency factors OCT4 and NANOG are regulated by epigenetic mechanisms, and 
their silencing by methylation may play an important role in differentiation of embryonic 
stem cells (Hattori et al., 2007; Hattori et al., 2004). 
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1.1.5                      B-Myb   
Recently, the transcription factor B-Myb has been associated with maintaining pluri-
potency, normal cell cycle progression and chromosomal stability of embryonic stem 
cells (Tarasov et al., 2008). Furthermore it plays an important role in somatic cell differ-
entiation, cell cycle progression and apoptosis (Joaquin and Watson, 2003; Oh and 
Reddy, 1999; Sala, 2005). 
B-Myb, also known as avian myeloblastosis viral oncogene homolog-2 (mybl2), belongs 
to the myb gene family that includes A-Myb and c-myb. All three members encode 
nuclear proteins, which act as transcriptional transactivators in different tissues. C-myb 
is critical for hematopoiesis, and shows therefore high expression levels in immature 
hematopoietic cells, whereas A-Myb is important for spermatogenesis as well as mam-
mary gland proliferation, and thus highly expressed in male germ cells and female 
breast ductal epithelium. In contrast to this tissue-specific expression, B-Myb is present 
in all proliferating cells. Furthermore, it is essential for formation and continued growth of 
the inner cell mass and, importantly, B-Myb is the only member of its family expressed in 
embryonic stem cells (Oh and Reddy, 1999; Tanaka et al., 2008). 
As per description, B-Myb is directly regulated by E2F transcription factors, and there-
fore transcribed constitutively in embryonic stem cells due to the inactivation of the pRB-
E2F pathway. By contrast, the expression of B-Myb in somatic cells is dynamically reg-
ulated in connection with the cell cycle, and is maximally induced at the G1/S boundary 
(Joaquin and Watson, 2003; Sala, 2005). For this reason, its functions were initially 
thought to be restricted to the progression from G1 to S phase, but in the meantime 
several studies have shown the important role for the G2/M transit. 
In Zebrafish embryos, a loss-of-function mutation in B-Myb (crash&burn mutants) 
causes defects in mitotic progression, spindle formation and genomic instability 
(Shepard et al., 2005). Studies in Drosophila have shown that dMyb (homologue to B-
Myb) mutants generate spindle defects and ploidy abnormalities (Manak et al., 2002). 
Furthermore mouse embryos lacking B-Myb die shortly after implantation because of 
inner cell mass defects (Tanaka et al., 1999).  
Since B-Myb is highly expressed in ES cells, recent studies have focused on its function 
in those cells. However, previous publications conclude partially different results follow-
ing B-Myb ablation.  
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Tarasov et al. state that knockdown of B-Myb in mES cells by short hairpin RNA leads to 
a transient but significant decreased transcription of SOX2 and OCT4, and subsequently 
to an upregulation in gene markers of differentiation. In contrast, Lorvellec et al. 
generated genetically modified embryonic stem cells lacking any expression of B-Myb. 
In these cells, they could not demonstrate any effect of B-Myb on the expression of 
pluripotency factors such as OCT4. 
Apart from that, both studies show the influence of B-Myb in cell cycle progression. Ab-
lation of B-Myb in mES cells results in abnormalities of S phase such as stalling of repli-
cation forks and superactivation of replication factories that causes disorganization of 
the replication program and an increase in double-strand breaks. These findings are 
partly the consequence of abnormal transcriptional regulation of proliferation factors like 
c-Myc and FoxM1, which are normally responsible for S phase progression (Lorvellec et 
al., 2010). B-Myb knockdown by shRNA leads to major cell cycle defects like a reduction 
of cells in G1 and S phase, and a delayed transit through G2/M with an accumulation of 
cells. These mitotic cells show centrosome and spindle defects, which causes an in-
crease in polyploidy. This chromosomal constitution containing multiples of the normal 
number of chromosomes results either in programmed cell death or sustained aneu-
ploidy (Tarasov et al., 2008). Apoptosis is only activated upon differentiation, and thus 
related to the establishment of robust cell cycle checkpoints in somatic cells (Mantel et 
al., 2007). 
Since Cyclin B1 is normally activated by B-Myb in late S phase, the absence of this 
transcription factor causes decreased Cyclin B1 transcripts, and the observed mitotic 
defects in ES cell lacking B-Myb are at least partially due to this protein (Boheler, 2009; 
Tarasov et al., 2008). 
In summary, the transcription factor B-Myb is required for maintenance of pluripotency, 
chromosomal integrity and normal cell cycle progression. Moreover, downregulation of 
B-Myb appears to be one of the earliest markers of pluripotent cell differentiation. 
Recent studies in somatic cells have shown that B-Myb promotes its function as a part of 
the LINC complex. This dynamic DNA binding complex comprises a five protein core 
module (Lin-9, Lin-37, Lin-54, Lin-52 and RbAp48) that associates with p130, E2F4 and 
B-Myb in a cell cycle dependent manner in order to regulate gene expression (Litovchick 
et al., 2007; Schmit et al., 2007). 
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In G1 phase this multiprotein complex binds with p130 and E2F4 resulting in the repres-
sion of E2F target genes, which regulate the progression from G1 to S phase (Litovchick 
et al., Pilkinton et al., 2007).   
Owing to the binding of B-Myb, the LINC complex is no longer transcriptionally repres-
sive, but switches to a transcriptionally active complex in S-G2 phase (Knight et al., 
2009). Beyond that, B-Myb recruits a Lin-9 complex to activate transcription of G2/M 
genes in undifferentiated embryonal carcinoma cells. Therefore both B-Myb and Lin-9 
are required for transition through mitosis in pluripotent cells without a robust G1/S 
checkpoint (Knight et al., 2009). 
 
The important role of the transcription factor B-Myb in regulating gene expression has 
been shown in preliminary ChIP on chip data (a genomescale location analysis by 
chromatin immunoprecipitation coupled with DNA microarrays). There it was described 
that B-Myb binds to over 240 promoter regions in mouse embryonic stem cells with a 
high degree of confidence. In the absence of B-Myb approx. 95 % of these genes pos-
sess reduced binding. Moreover a significant part of those proteins is either associated 
to the cell cycle or implicated in differentiation (64 out of 240). Target genes associated 
with the cell cycle include e.g. the members of the chromosomal passenger complex 
(Aurora Kinase B, INCENP, Borealin), centrosome associated kinases like Aurora 
Kinase A and signaling molecules such as Cyclin B1.  
But it is still unclear whether the chromosomal aneuploidy that accompanies B-Myb defi-
ciency is due to a generalized reduction in proteins required for G2/M progression or 
whether the dysregulation of individual factors like Cyclin B1 or Aurora Kinase A is 
responsible for the aneuploidy. 
Therefore the ChIP-on-chip analyses have led to the hypothesis that the transcription 
factor B-Myb directly regulates gene expression of these proteins, and that their 
dysregulation leads directly to chromosomal instability, which can result in the genera-
tion of defective stem and somatic cell populations that have the potential to be pro-
oncogenic  
Based on depressed protein and RNA expression in ES cells lacking B-Myb, the atten-
tion is therefore focused on Aurora Kinase A and Cyclin B1. 
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1.1.6                      Aurora Kinase A 
The Aurora family of serine-threonine kinases consists of three members: Aurora Kinase 
A, B and C. They all share similar structures ‒  highly conserved catalytic domains 
flanked by very short C-terminal tails and N-terminal domains of variable length. Be-
sides, all three members vary in their expression patterns, subcellular localization and 
time of activation (Marumoto et al., 2005). 
Aurora Kinase A plays a significant role in mitotic regulation and carcinogenesis. Its 
various functions include centrosome maturation and segregation, bipolar spindle as-
sembly, chromosome alignment, the transition from prophase to metaphase and cytoki-
nesis (Berdnik and Knoblich, 2002; Giet et al., 2002). In order to fulfill its task Aurora-A 
localizes to centrosomes during interphase of the cell cycle, and connected with the on-
set of mitosis Aurora-A is found at both spindle poles as well as spindle microtubules 
(Gopalan et al., 1997; Kimura et al., 1997; Zhou et al., 1998).  
Due to its role in mitotic regulation the transcription of Aurora-A is cell-cycle dependent 
with a low expression in G1/S phase, maximum at G2/M phase and a rapidly decrease 
toward the end of mitosis (Bischoff et al., 1998; Kimura et al., 1997). Since the E2F 
family of transcription factors regulates the expression of genes that are required for 
DNA replication and mitosis, Aurora Kinase A is also one of their target genes. E2F3 
modulates Aurora-A expression by upregulating its transcription during G2 and the be-
ginning of mitosis (He et al., 2007). Moreover, the activity of Aurora Kinase is regulated 
by phosphorylation, and after mitosis is finished there are two ways of degradation: both 
the ubiquitin-mediated proteolysis and an ubiquitin-independent mechanism.  
Furthermore previous studies have shown the importance of the accurate timing as well 
as the definite level of Aurora Kinase A expression to maintain a regular progression 
through mitosis. Aurora-A deletion in mouse embryonic fibroblast causes delayed mitotic 
entry, mitotic arrest with accumulation of cells in early prophase as well as defects in 
bipolar spindle formation. The fact that Aurora-A deficient cells were not observed in any 
phases of the cell cycle later than prometaphase indicates that those cells exit mitosis 
without cell division. Additionally, Aurora-A deletion in midgestation embryos results in 
an increased number of mitotic and apoptotic cells (Cowley et al., 2009). Germ line 
Aurora Kinase A deficiency leads to embryonic death at blastocyst stage due to mitotic 
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arrest and monopolar spindle formation (Cowley et al., 2009). This enzyme is thus es-
sential for embryonic development.  
 
On the contrary, overexpression of Aurora Kinase A leads to centrosome amplification 
and causes aneuploidy, which results in either growth arrest, cell death or survival 
through malignant transformation (Mao et al., 2007; Meraldi et al., 2004). Ectopic ex-
pression of Aurora-A causes increased centrosomes with associated loss or gain of 
chromosomes that finally leads to oncogenic transformation as well. In fact, this enzyme 
has been found frequently amplified and overexpressed in many human cancers, for 
instance breast, colorectal, pancreatic and bladder cancer, that correlates with clinically 
aggressive disease and poor prognosis (Katayama et al., 2003). Since aberrant Aurora-
A expression is associated with tumorigenesis, Aurora Kinase Inhibitors have been de-
veloped in order to stop cancer cell growth, and have recently entered clinical trials 
(Boss et al., 2009). 
A thorough understanding of the relevant molecular pathways involving Aurora Kinase A 
is therefore very important to understand its entire function in mitotic regulation, and the 
Aurora-A induced tumorigenic transformation process. 
  
1.1.7                      Cyclin B1 
As mentioned previously, cell cycle transition is regulated by the periodic activation and 
inactivation of Cyclin/Cdk (Cyclin-dependent kinase) complexes at defined phases of the 
cell cycle.  
In contrast to somatic cells, all Cyclin/Cdk-complexes in embryonic stem cells show con-
stant activity throughout the cell cycle except for the Cyclin B1/Cdk1 complex. This com-
plex regulates mitotic entry as well as progression through mitosis (Nurse, 1990). 
Levels of Cyclin B1 increase during G2 phase resulting in an accumulation of Cyclin B1-
Cdk1 complexes that are still inactivated (Pines and Hunter, 1989). Subsequently, 
dephosphorylation by Cdc25 phosphatases leads to gradually increased activity and, 
after a certain threshold activity is reached, further activation of Cyclin B1/Cdk1-complex 
is catalyzed by a positive-feedback loop (Boutros et al., 2006; Solomon et al., 1990). At 
first, this highly activated complex localizes to the centrosomes and triggers their sepa-
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ration in late G2 or prophase (Blangy et al., 1997; Crasta et al., 2006; Jackman et al., 
2003). Accordingly, owing to phosphorylation the Cyclin B1/Cdk1-complex is translo-
cated into the nucleus, where it leads to enhanced chromosome condensation and 
nuclear envelope breakdown (Hagting et al., 1999; Li et al., 1997). Afterwards the two 
sister chromatids of each chromosome need to be correctly attached to opposite spindle 
poles (Pines, 2006; Taylor et al., 2004). This process is controlled by the mitotic spindle 
checkpoint, which inhibits Cyclin B1 destruction and Cdk1 inactivation and stops cell 
cycle progression as long as all chromosomes are connected to the correct mitotic 
spindles. If all requirements for the checkpoint are complied with, decreased Cyclin 
B1/Cdk1 activity is essential for chromosome segregation and completion of cell division 
(Pines, 2006).   
  
Importantly, Cyclin B1 is a known target for the transcription factor B-Myb, it shows high 
expression levels in ES cells and is downregulated upon differentiation just like B-Myb. 
Additionally the observed mitotic defects in G2/M phase caused by B-Myb knockdown 
were in part ascribed to Cyclin B1. 
  
1.2 Inducible Expression System 
To accurately analyze the function of specific genes in mammalian cell culture systems, 
it is critical to tightly regulate their expression. Therefore the use of an inducible expres-
sion system employing regulatory elements of the tetracycline resistance operon is very 
helpful.  
In this study the cell line Ainv15 was planned to generate for a stronger knockdown of B-
Myb and its target genes (see results): however, the data generated with this system 
occurred after the allotted time for completion of my studies.  
 
1.3       MicroRNA 
MicroRNAs (miRNA) are a group of short ~22 nucleotide RNA molecules encoded in the 
genome of animals and plants. These nonprotein-coding RNAs regulate gene expres-
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sion by binding to complementary sequences in the 3’-untranslated region (3’ UTR) of 
specific mRNAs, resulting in their being silenced.  
MicroRNAs were first discovered in 1993, and since then more than 700 miRNAs have 
already been identified in humans and several hundreds more are predicted to exist. 
They have a wide range of functions, and act as key regulators for instance in cell 
proliferation and cell death, early development, cell differentiation or brain development. 
Furthermore, miRNA dysregulation is also associated with different kinds of diseases 
such as viral infection, chronic lymphocytic leukemia or colonic adenocarcinoma. 
MiRNAs have to undergo a multistep posttranscriptional modification before they can 
function as active single-stranded miRNAs. They are initially expressed as primary 
transcripts (pri-miRNA) containing 5’caps and 3’poly-A-tails by RNA-Polymerase II (Cai 
et al., 2004; Lee et al., 2002; Smalheiser, 2003). The miRNA part of the pri-miRNA 
transcript forms a hairpin loop structure, which is recognized by the dsRNA-specific 
ribonuclease Drosha. This enzyme digests the pri-miRNA in the nucleus and releases 
the hairpin, precursor miRNA (pre-miRNA) (Lee et al., 2003). Pre-miRNAs consist of 
approximately 70 nucleotides (nt) with 2 nt 3’overhangs and a stem loop structure. In the 
next step the pre-miRNA is transported to the cytoplasm by Exportin-5/Ran-GTP (Yi et 
al., 2003). Afterwards the endonuclease Dicer cleaves the pre-miRNA stem loop, so that 
two complementary short RNA molecules are formed (Bernstein et al., 2001; Hutvágner 
et al., 2001). Only one of the two strands associates with the RNA-induced silencing 
complex (RISC) (Hutvágner and Zamore, 2002). This mature mi-RNA guides the RISC 
to target genes in order to induce post-transcriptional gene silencing.  
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Figure 2: MiRNA processing pathway (Applied Biosystems, 2010) 
 
To detect their targets, the 5’ nucleotides 2-7 (known as ‘seed region’) of the miRNA 
have to be perfectly or near perfectly complementary to the messenger RNA.  
The dimension of complementarity is implicated as an important factor in the mechanism 
of posttranscriptional repression by miRNAs. Perfect complementarity leads to mRNA 
cleavage, whereas near perfect binding excludes cleavage and causes inhibition of the 
mRNA translation (Carthew and Sontheimer, 2009). 
Importantly, the miRNA pathway is a useful system to knockdown a gene of interest and 
study its function in cell culture. 
  
1.4       Aim of the study  
The aim of the study was to determine how B-Myb regulates transit through the G2/M 
phase of ES cells to maintain euploidy. More specifically, previous data has shown that 
knockdown of the transcription factor B-Myb in ES cells causes major cell cycle defects 
and polyploidy accompanied by reduced levels of target genes such as Aurora Kinase A 
and Cyclin B1. Therefore the question has been raised whether those target genes con-
tribute to the phenotype seen by B-Myb knockdown.  
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To clarify the roles of putative B-Myb target genes, miRNAs directed against Aurora 
Kinase A and Cyclin B1 have been designed and tested in transient transfections. Since 
miRNAs can affect other target genes, the ones with the best knockdown efficiency and 
the least promiscuity were chosen. In order to mimic the results seen with B-Myb knock-
down, protein levels of Aurora Kinase A and Cyclin B1 were decreased by miRNA 
knockdown to levels comparable to those seen in B-Myb deficient cells. Subsequently 
the best miRNAs were nucleofected into mES cells to study their function by cell cycle 
and spindle assembly analysis. The main objective at this juncture was to explore 
whether knockdown of Aurora Kinase A and/or Cyclin B1 leads to similar effects com-
pared to the B-Myb knockdown, such as aneuploidy, changes in cell cycle and 
centrosome/ spindle defects. 
At the same time the B-Myb shRNA, which was already designed in previous experi-
ments by others, was nucleofected in mES cells as well in order to compare cell cycle 
and spindle analysis. 
Finally, it was planned to generate the constructs for the Ainv15 cells that are regulated 
by the reverse tetracycline transactivator to drive expression of transgenes that knock-
down B-Myb or one of the target genes using miRNAs. Thus, a more complete knock-
down of Aurora Kinase A and Cyclin B1 would be achieved, since shRNA and miRNA 
only partially decrease their targets. Secondly, different target genes of B-Myb detected 
with the help of microarray analysis could be tested similarly.  
 
Since the time working on my project at the National Institute on Aging was limited to six 
months, it was not possible to complete the planned generation of the Ainv15 cells 
during my stay. Anyhow, I finished cell cycle and spindle assembly analysis using the 
designed miRNAs for Aurora Kinase A as well as Cyclin B1 and compared the results to 
B-Myb knockdown.  
The experiments concerning Ainv15 cells have been completed by others since I left the 
laboratory. 
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2. Methods 
2.1  DNA Plasmid Preparation 
Plasmid DNA was cultured overnight at 37°C in LB media containing Spectinomycin. In 
order to isolate a high quantity of Plasmid DNA from maxi-cultures the GenElute HP 
Endotoxin-Free Plasmid Maxiprep Kit was used, and to extract Plasmid DNA from mini-
cultures for analytical purposes the QuickGene Plasmid kit S II (Fujifilm) was employed. 
The functional principle of both Kits is to lyse the cells under alkaline conditions and 
neutralize the solution in the next step to precipitate chromosomal DNA and proteins. In 
contrast Plasmid DNA has the ability to renature rapidly after denaturation and to stay in 
solution, so that it can be easily extracted from the bacterial chromosomal DNA. There-
fore the Plasmid DNA was absorbed by a binding column and contaminants were eluted 
by two washing steps.  
Finally, the isolated DNA was quantified with the help of a spectrophotometer e.g. 
Genequant pro, which measures the absorbance at 260 and 280 nm, to determine the 
concentration.  
 
2.2  Gel electrophoresis 
Agarose gel electrophoresis is a common technique to separate DNA fragments ac-
cording to their sizes. Upon application of an electric current, the negatively charged 
DNA moves through the gel pores toward the positive pole (anode) of the electro-
phoresis chamber. Smaller molecules move more easily through the porous lattice than 
larger molecules. Therefore the fragments can be separated into distinct bands accord-
ing to their molecular weight. 
Basically, fragments of linear DNA migrate with a mobility that is inversely proportional to 
the log10 of their molecular weight. In comparison, circular forms of DNA migrate much 
differently to linear DNA of the same mass. The migration of an uncut plasmid will ap-
pear more rapidly than the same vector when linearized by restriction enzymes. Most 
preparations of uncut plasmid contain at least two different forms of DNA: the super-
coiled form and nicked circles. When these plasmids are cut and thus linearized they all 
become identical, and one then observes only one band on the gel.  
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In order to visualize the gel with UV light, the DNA has to be stained with a fluorescent 
dye. Ethidium bromide is commonly used for detecting DNA, because it intercalates 
between bases of nucleic acids and therefore strongly enhances the staining. 
The DNA was separated by 0.5-2 % agarose gel electrophoresis (Ultra Pure Agarose by 
Invitrogen) and 0.2 µg/ml ethidium bromide in TBE Buffer (Tris-Borate EDTA). The gels 
were run at 80-120 V for 45-90 min.  
 
2.3  Transfection 
Transfection describes the process of bringing foreign DNA into cells. There are several 
different methods for introducing DNA into cells concerning e.g. the type of carrier, which 
is used. FuGENE 6 Transfection Reagent (Roche) consists of a blend of lipids that forms 
a complex with the Plasmid DNA. After fusing with the cell membrane the Plasmid DNA 
is released into the cell where it can be expressed with the help of the cell’s transcription 
apparatus. 
Protocol:   
35mm culture dishes containing a monolayer of C2C12 cells, that is 50-80 % confluent 
were used for transfection. The Ratio of µl Transfection Reagent : µg DNA was chosen 
at 3:1. First of all, the Transfection Reagent was diluted with serum-free medium and 
subsequently the DNA was added. The complexes were allowed to form during an incu-
bation period of 15 minutes at room temperature before being added to the cells.  
 
2.4  Nucleofection 
Nucleofection is a transfection method with which the substrate, such as Plasmid DNA, 
is transferred directly into the cell nucleus and the cytoplasm. Contrary, other transfec-
tion methods depend on cell division for the purpose of transferring DNA into the 
nucleus. Predominantly, nucleofection is considered for cell lines that are very difficult to 
transfect, for instance stem cells.  
The Amaxa Nucleofector technology is based on electroporation, and contains various 
profiles as well as several nucleofector solutions, which are defined for specific cell 
types. 
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Protocol: 
Cells were harvested by trypsinization, and then pelleted via centrifugation. In order to 
resuspend cells the appropriate nucleofection solution was chosen, and afterwards the 
Plasmid DNA was added. Subsequently, the electroporation was carried out either by 
using the Nucleofector or the 96 well shuttle system depending on the number of 
samples. Cells were transferred into culture dishes, incubated at 37°C and selection 
reagents were added 24h after nucleofection. Puromycin was used for cells 
nucleofected with B-Myb shRNA and pSuper, and Blasticidin was taken as selection 
reagent for cells nucleofected with miR neg, Aurka and Ccnb1. 
  
2.5 Western Blot 
As an analytical technique the Western immunoblotting is used to detect a specific pro-
tein in a given sample. Furthermore the molecular weight of a protein can be determined 
and relative amounts of the protein can be compared in different samples.  
The isolated proteins are separated using SDS-polyacrylamide gel electrophoresis, 
which primarily denatures all proteins to their primary structure. For the purpose of 
making the proteins accessible to antibody detection, they are then transferred onto a 
PVDF membrane. An electric field is applied to the gel, and the separated proteins move 
to the positive charged membrane, retaining the same pattern of separation as they had 
on the gel. Afterwards the membrane is placed in a blocking solution to prevent non-
specific binding between the membrane and the antibody. In order to detect the desired 
antigen, the primary antibody is added and forms a complex with the antigen. Subse-
quently the membrane is exposed to the secondary antibody to detect the bonded 
primary antibody. The secondary antibody is a species-specific anti-immunoglobulin that 
contains the reporter enzyme, such as horseradish peroxidase. Finally, the substrate for 
the reporter enzyme is added; luminescence is produced wherever there is an antigen-
antibodies-complex. By exposing the membrane to photographic film one can visualize 
the bands. 
Protocol: 
The Cells were trypsonized, washed with PBS (pH 7.4) and harvested. According to the 
size of the pellet 50-500 µl Cell ‘RIPA’ buffer was added to resuspend the cells. After 
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incubation on ice with occasional vortexing for 30 min, the samples were centrifuged at 
4°C and 10,000 g for 10 min and the supernatant including the protein lysate was trans-
ferred to a new tube. In order to determine the protein concentration Bio-Rad DC Protein 
Assay was used. 
Subsequently the samples were diluted to a total protein amount of 25-50 µg, solubilized 
by heating for 5 min at 95°C and loaded along with the molecular weight marker onto a 
precast Criterion 18 well 7.5 %/4 % Tris-HCl SDS-Page mini-gel (Bio-Rad). To separate 
proteins the gel was run at constant voltage, initially at 60 V for 30 min and then at 120 V 
for 1.5 hours. Afterwards the protein bands were blotted onto a PVDF membrane pre-
soaked in 100 % methanol using Bio-Rad Criterion Mini Trans-Blot Electrophoretic 
Transfer Cell Apparatus and Accessories. To transfer the proteins to the membrane, the 
gel was run at a constant current of 250 mA for 2.5 hours.  
Since both antibodies are proteins as well, and the membrane serves the purpose of 
binding proteins, all sorts of other interactions must be prevented. Therefore the mem-
brane was placed for 1 hour into a blocking solution containing 5 % dried milk, so that 
the protein of this solution can bind to the membrane and cover all the free places to 
which the target proteins have not attached themselves.  
Next, the membrane was incubated overnight at 4°C rocking in primary antibody 
solution. After washing three times for 10 minutes in PBS/T, it was incubated for 1 hour 
at room temperature in horse radish peroxidase (HRP) conjugated secondary antibody 
solution.  
Subsequently, the membrane was washed again three times in PBS/T, and then incu-
bated for 30 seconds in Pierce Supersignal ECL Horse Radish Peroxidase substrate 
solution. This substrate is oxidized by HRP, producing luminescence in proportion to the 
amount of protein present, which can be detected on a photographic film.  
 
2.6  Cell Cycle Analysis 
Cell Cycle Analysis is a quick method to quantify the relative nuclear DNA content and 
ploidy level of a cell population by flow cytometry.  
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First of all, single cells are stained with a fluorescent dye e.g. Propidium Iodide, which 
binds stoichiometrically to the DNA. Afterwards the stained material is measured by flow 
cytometry, and the replication state of the cells can be analyzed. 
Protocol: 
Cells were trypsonized, washed with PBS (pH 7.4) and harvested. Subsequently the 
cells were fixed in methanol and stored at -20°C. After this, the cells were washed with 
three times with PBS, one million of the cells were stained with Propidium Iodide, and 
measured by flow cytometry using Becton Dickinson FACs CANTO II. 
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3. Materials 
3.1  Laboratory apparatus 
Daigger Vortex Genie 2 (A. Daigger & Co, Inc) 
Centrifuge 5415C (Eppendorf) 
Sorvall RC 5C Plus (Heraeus & Sorvall) 
GPKR Centrifuge (Beckman) 
IEC Clinical Centrifuge (International Equipment Company) 
Type 16500 Dri-Bath (Thermolyne) 
All Stainless Steel Water Bath Model 181 (Precision) 
Gel Pump GP 110 (Savant) 
Gene Quant pro (Pharmacia Biotech) 
Spectrophotometer DU-640 (Beckman) 
Gel Doc 1000 (Bio Rad) 
Power Pac 3000 (Bio Rad) 
Model 200/2.0 Power Supply (Bio Rad) 
AE 240 Analytical Balance (Mettler) 
BP 210D (Sartorius) 
Hot Shaker (Bellco Glass, Inc) 
Mini Trans-Blot Electrophoretic Transfer Cell Apparatus and Accessories (Bio Rad) 
Axio Observer A1 (Zeiss) 
Axiovert 35 (Zeiss) 
Mini Medicla Series (AFP Imaging) 
Fixer ChemBlend (H.R. Simon and Company Inc.) 
CB2 Developer (H.R. Simon and Company Inc.) 
Becton Dickinson FACs CANTO II (BD Biosciences) 
 
3.2  Kits 
BLOCK-iT Pol II miR RNAi Expression Vector Kit (Invitrogen) 
QuickGene Plasmid Kit S II (Fujifilm) 
Gen Elute HP Endotoxin-free Plasmid Maxiprep Kit (Sigma-Aldrich) 
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FuGENE 6 Transfection Reagent (Roche) 
Mouse ES Cell Nucleofector Kit (Amaxa) 
Mouse ES Cell 96-well Nucleofector Kit (Amaxa) 
DC Protein Assay Kit (Bio Rad) 
 
3.3  Enzymes 
Xho I (Promega) 
Sal I (Promega) 
 
3.4  Antibodies 
Mouse monoclonal to Aurora A (Abcam) 
Rabbit polyclonal to Cyclin B1 (Santa Cruz Biotechnology) 
Rabbit polyclonal to B Myb (Abcam) 
Rabbit polyclonal to Oct4 (Abcam) 
Mouse to GAPDH (Sigma) 
Goat anti-mouse IgG HRP Conjugate (Invitrogen) 
Goat anti rabbit IgG HRP Conjugate (Invitrogen) 
α-Tubulin (Sigma) 
γ-Tubulin (Sigma) 
 
3.5  Reagents 
TE pH 7.4 (Quality Biological Inc) 
Tris-Borate EDTA (TBE) 10X Solution (Fisher Scientific) 
Ethyl Alcohol 200 Proof (The Warner-Graham Company) 
Isopropanol (J.T. Baker) 
Methanol (Fisher Scientific) 
Acetone (Sigma) 
Sodium Acetate pH 5.2 (Quality Biological Inc) 
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Glycerol (Life Technologies) 
PBS pH 7.4 (GIBCO) 
0.25 % Trypsin-EDTA (GIBCO) 
Buffer D 10X (Promega) 
Ultra Pure Agarose (Invitrogen) 
Ethidium Bromide Solution 10mg/ml (Research Genetics) 
10X Blue Juice Gel Loading Buffer (Invitrogen)  
Sodium Chloride (Fisher Scientific) 
Bacto Tryptone (BD) 
Bacto Yeast Extract (BD) 
Bacto Agar (BD) 
1 kb DNA Ladder (Invitrogen) 
50 bp DNA Ladder (Invitrogen) 
25 bp DNA Step Ladder (Promega) 
Precision Pure Protein Dual Color Standards #161-0374 (Bio Rad) 
Blasticidin S HCl (GIBCO) 
Spectinomycin (Invitrogen) 
Puromycin (Invitrogen) 
Ribonuclease A (Sigma) 
Dapi (Sigma) 
Vectashield mounting medium for fluorescence (VECTOR) 
Propidium iodide (Sigma) 
Paraformaldehyde (Fisher Scientific) 
Glycine (Sigma) 
1 % Triton X100 (Sigma) 
Cell RIPA Buffer (Sigma) 
Nupage LDS Sample Buffer 4x (Invitrogen) 
DTT (Sigma) 
Precision Plus Protein All Blue Standards (Bio-Rad) 
10x Tris/ Glycine/ SDS Buffer (Bio-Rad) 
Blotting Grade Blocker non-fat dry milk (Bio-Rad) 
Tween 20 (Sigma-Aldrich) 
SuperSignal West Pico Chemiluminescent Substrate (Thermo Scientific) 
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Restore Western Blot Stripping Buffer (Thermo Scientific) 
 
3.6  Cell lines 
C2C12 
R1 
 
3.7  Cell culture media 
2X LIF media (Sigma) 
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4. Results 
4.1 Nucleofections 
4.1.1   Testing miRNAs for Aurora Kinase A knockdown 
The purpose of my study was to mimic the results observed by B-Myb knockdown in 
mES cells. Since protein levels of specific target genes such as Aurora Kinase A or 
Cyclin B1 were reduced in B-Myb deficient cells, miRNAs were designed and used ini-
tially to knockdown those target genes to similar levels in order to detect whether an 
identical phenotype could be reproduced.  
Therefore miRNA vectors directed against Aurora Kinase A and Cyclin B1 were 
generated; these are described in detail in a following chapter of the result section. 
In order to identify whether the designed miRNA constructs achieve a successful knock-
down of the target gene Aurka, R1 cells were nucleofected with each of the five vectors 
(pc DNA 6.2-GW/EmGFP miR Aurka 398, 555, 702, 1154 and 1276). R1 cells without 
nucleofection served as a negative control as well as the pc DNA 6.2-GW/EmGFP miR 
negative plasmid, because its insert processed into mature miRNA does not target any 
known vertebrate gene.  
The cells were harvested 24, 48 and 72h after selection and protein expression was 
detected by Western immunoblotting.   
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Figure 3: Western Blot showing knockdown of Aurora Kinase A at 48h after selection. 
 
Western immunoblotting enables a comparison of efficiency of Aurora Kinase A knock-
down achieved by the five different miRNAs.  
R1 cells without nucleofection and R1 cells nuclefected with the empty vector control 
clearly displayed regular expression of Aurora Kinase A. In contrast, all five miRNAs de-
creased the quantity of Aurora Kinase A compared to control cells, but knockdown with 
miRNA 702 caused lowest protein levels with a significant reduction of Aurora Kinase A 
transcripts by 60 % relative to miR neg. This miRNA proved most effective for knock-
down of Aurora Kinase A, and was used for further analysis.  
 
4.1.2   Testing miRNAs for Cyclin B1 knockdown 
In an analogous way, it was checked whether the designed miRNA constructs achieve a 
successful knockdown of the target gene Ccnb1. R1 cells were nucleofected with each 
of the three vectors (pc DNA 6.2-GW/EmGFP miR Ccnb1 682, 744, 826). Again, R1 
cells without nucleofection served as a negative control as well as the pc DNA 6.2-
GW/EmGFP miR negative plasmid. The cells were harvested 24, 48 and 72 h after se-
lection and protein expression was detected by Western immunoblotting.   
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Figure 4:  Western Blot showing knockdown of Cyclin B1 at 48h after selection. 
 
R1 cells without nucleofection as well as R1 cells nucleofected with the empty vector 
control showed regular expression of Cyclin B1. By comparison, all R1 cells 
nucleofected with the three pcDNA 6.2-GW/EmGFP miR Ccnb1 vectors displayed lower 
levels of the target gene, but knockdown by miRNA 682 reduced Cyclin B1 expression 
most efficiently, leading to a significant reduction of Cyclin B1 transcripts by 55 % rela-
tive to miR neg. Therefore this miRNA was used for further analysis. 
 
4.2 Comparing levels of B-Myb, Aurora Kinase A and Cyclin B1 by 
knockdown 
Silencing gene expression of a certain target gene via RNA interference does not only 
lead to a reduced level of that specific protein, but can also cause decreased expression 
of other genes. For instance, previous experiments have shown that knockdown of B-
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Myb by shRNA results in decreased levels of target genes such as Cyclin B1, due to the 
fact that B-Myb regulates gene expression of those target genes. 
Thus it was important to check whether knockdown of Aurora Kinase A or Cyclin B1 by 
the designed miRNAs leads to equal protein levels compared to those seen in B-Myb 
deficient cells.  
In order to compare knockdown efficiency, R1 cells were nucleofected with vectors 
containing miR Aurka 702, miR Ccnb1 682 as well as a vector containing shRNA for B-
Myb knockdown. (This shRNA was already employed by Tarasov et al. in previous ex-
periments to knockdown B-Myb.) R1 cells nucleofected with the miR neg vector served 
as a negative control for Aurka and Ccnb1. The empty vector, pSuper, was nucleofected 
into R1 cells as well and served as a negative control for B-Myb shRNA.  
Cells were harvested 48 h after selection and protein expression was detected by 
Western immunoblotting. 
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Figure 5: Protein Expression 72 hours after nucleofection. Significance levels p<0,05:   
* = compared to control, + = compared to B-Myb shRNA, # = compared to miR Ccnb1,  
• = compared to miR Aurka.  
 
In R1 cells nucleofected with B-Myb shRNA, B-Myb expression was completely elimi-
nated. Additionally, Cyclin B1 levels were also decreased to 80 % whereas Aurora 
Kinase A protein expression was not significantly reduced.  
By comparison, nucleofection with miR Ccnb1 led to Cyclin B1 reduction of 50 %. B-Myb 
and Aurora Kinase A levels were not significantly changed. R1 cells nucleofected with 
miR Aurka showed significantly decreased levels of Aurora Kinase A to 60 %. Loss of 
Aurora Kinase A also led to significantly reduced levels of B-Myb. Expression of Cyclin 
B1 was not affected in this regard. 
In summary, knockdown with the help of miRNA caused lower levels of Cyclin B1 and 
Aurora Kinase A compared to levels seen with B-Myb knockdown. 
 
4.3 Cell Cycle Analysis 
Cell cycle analysis is a useful technique to quantify the relative nuclear DNA content of a 
cell population and consequently distinguish cells in different phases of the cell cycle. 
After staining the cells with Propidium Iodide, which binds stoichiometrically to the DNA, 
the stained material is measured by flow cytometry, and the replication state of the cell 
population can be analyzed. 
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A regular cell cycle analysis displays three populations of cells representing G1-, S- and 
G2/M phase. G1 cells have one copy of DNA (2N) and thus show 1X fluorescence in-
tensity. Whereas cells in G2/M phase are ready to go into mitosis and contain two 
copies of DNA (4N) resulting in a 2X fluorescence intensity. Since cells in S phase are 
replicating the DNA, they have fluorescence values somewhere between 1X and 2X 
populations. The resulting histogram shows those three populations, in which the G1 
and G2/M cells are represented by Gaussian curves (see Figure 6).  
 
 
Figure 6: Cell Cycle Analysis. 
 
Furthermore flow cytometry can also detect changes in the number of chromosomes in a 
population of cells and is therefore competent to reveal aneuploidy, which is character-
ized by an abnormal number of chromosomes, or polyploidy, which describes cells with 
more than two homologous sets of chromosomes. 
Since polyploid cells have at least one full extra complement of chromosomes, one can 
observe an additional population in the histogram with a fluorescence intensity that is 
some multiple of 1X. In the case of polyploidy, there is also a population of cells repre-
senting a second S phase, when DNA is replicated from 4N to 8N (Figure 7). 
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Figure 7: Cell Cycle Analysis. 
 
Moreover, in all cell cycle analyses there is usually a population of cells to be seen in the 
S2 region. These cells have a PI staining higher than 4N, which can occur when dou-
blets (two cells stuck together) are read as a single cell by flow cytometer. The number 
of readings in this region is usually insignificantly small and thus left out in analysis, but 
since polyploidy was expected in this study the S2 phase is included. 
Furthermore it is possible to detect aneuploid cell populations by flow cytometry. Due to 
the fact that aneuploid cells have an abnormal number of chromosomes, the G1 or G2/M 
curve can either show two peaks or a broader side that is described as a shoulder. 
With the help of special software the percentages of cells occupying the different phases 
of the cell cycle can be calculated and thus analyzed. 
In this study, cell cycle analysis was used to test whether knockdown of Aurora Kinase A 
or Cyclin B1 leads to major cell cycle defects or polyploidy.  
R1 cells were nucleofected with both vectors (pcDNA 6.2-GW/EmGFP miR Aurka 702 
and Ccnb1 682). As a negative control for Aurora Kinase A and Cyclin B1, R1 cells were 
nucleofected with the miR neg vector.  
In order to compare resulting data to the phenotype seen by B-Myb knockdown, R1 cells 
were nucleofected with a B-Myb shRNA vector as a positive control. The empty vector, 
pSuper, was nucleofected into R1 cells as well and served as a negative control for B-
Myb shRNA.  
Cells were harvested 24, 48 and 72 h after selection, stained with Propidium Iodide and 
cell cycle analysis was run afterwards.  
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Figure 8: Cell cycle analysis: Percentages of cells occupying the different phases of the cell 
cycle. 2N = normal set of chromosomes in non-dividing cells, representing G1 phase. S1 = S 
phase, DNA replication. 4N = duplicated set of chromosomes, representing G2/M phase. S2 = 
cells having fluorescence values higher than 4N. 8N = 4 sets of chromosomes, polyploid cells.  
 
R1 cells nucleofected with the pSuper control showed a regular cell cycle for embryonic 
stem cells. The rapidly dividing mES cells have short cell cycle duration (~8-10hrs) and 
tend to have relatively short G1 and G2/M durations with the majority of cells in S phase. 
These characteristics are shown for pSuper (Figure 8): more than 50 % of the cells are 
in S phase and the amount of cells in G1- and G2/M phase is clearly lower. No abnormal 
polyploidy cell population can be observed for pSuper. 
By contrast, R1 cells nucleofected with B-Myb shRNA showed major cell cycle defects 
such as a decrease of cells in G1 and S, while having a significant increase of cells in 
G2/M with more than 50 % of cells in this phase of the cell cycle. The observed cell 
cycle characteristics could reveal a delayed transit through G2/M with an accumulation 
of cells as this was seen by Tarasov et al. 2008 as well. 
Since there was also a polyploid cell population (8N), in addition to a delay, the higher 
amount of cells containing a duplicated set of chromosomes (4N) also indicated an in-
crease in cells undergoing abnormal cell division. 
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Figure 9: Cell cycle analysis: Percentages of cells occupying the different phases of the cell 
cycle. 
 
 
R1 cells nucleofected with the miR neg as a negative control displayed a regular cell 
cycle for mouse embryonic stem cells as seen for pSuper as well. Most of the cells were 
in S phase and due to short generation times with almost eliminated gap phases the 
quantity of cells in G1 and G2/M is smaller.  
The embryonic stem cells nucleofected with miR Aurka 702 and miR Ccnb1 
682 respectively both showed a regular cell cycle that was comparable to the negative 
control. Major cell cycle defects such as a delay in a specific phase or a significant 
polyploid population were not observed.  
 
4.4 Spindle-Assembly Analysis 
Spindle-assembly analysis is a method to visualize by immunofluorescence microscopy 
whether the spindle apparatus and chromosomes are arranged properly during mitosis. 
Moreover, the relative quantity of cells undergoing the different stages of mitosis can be 
counted and analyzed by this technique. 
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The process of mitosis can be divided into four principal stages and each stage can be 
identified with the help of defined characteristics such as centrosome and spindle for-
mation or chromosome alignment: 
In prophase chromatin condenses into chromosomes, the two centrosomes begin 
moving to opposite sides of the cell and the nucleolus disappears. In prometaphase, 
which is sometimes considered part of prophase, the nuclear envelope breaks down and 
microtubules emanating from the centrosomes attach to the kinetochores of the chromo-
somes. Subsequently, in metaphase, centrosomes start pulling the chromosomes 
toward the two ends of the cell. As a result, all chromosomes become aligned in the 
metaphase plate at the cell´s equator. Afterwards the cell proceeds to anaphase where 
paired chromosomes separate at the kinetochores and the single chromatids thus can 
now be considered individual chromosomes, and are pulled to opposite ends of the cell. 
When the separating chromosomes reach the poles in telophase, new nuclear 
envelopes form around each set. Chromosomes and spindle fibers disperse and the di-
vision of cytoplasm, cytokinesis, starts during this phase. 
For this purpose, R1 cells were nucleofected with both vectors (pcDNA 6.2-GW/EmGFP 
miR Aurka 702 and Ccnb1 682). In addition, R1 cells nucleofected with the miR neg 
vector served as a negative control.  
To compare resulting data to the phenotype seen by B-Myb knockdown in previous ex-
periments, R1 cells nucleofected with B-Myb shRNA vector were used as a positive 
control. The empty vector, pSuper, was nucleofected into R1 cells as well and served as 
a negative control for B-Myb shRNA.  
Cells were fixed with 4 % paraformaldehyde at 48 h after selection, and via α-tubulin, γ-
tubulin and DNA staining, the state of mitosis was analyzed by immunofluorescence 
microscopy. 
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Figure 10: Mitotic cells 72h after nucleofection. Cells are stained with DAPI (blue), gamma 
tubulin (red) and alpha tubulin (green). Bar = 20 µm. 
 
R1 cells nucleofected with miR neg and pSuper, as a negative control, showed regular 
characteristics in all stages of mitosis: normal bipolar centrosomes in prophase, regular 
alignment of chromosomes in the metaphase plate, bipolar mitotic spindle formation in 
anaphase and separating chromosomes reaching opposite poles in telophase (see 
Figure 10). 
 
 
Figure 11: Mitotic cells 72h after nucleofection. Cells are stained with DAPI (blue), gamma 
tubulin (red) and alpha tubulin (green). Bar = 20 µm. 
 
Similarly, R1 cells nucleofected with miR Aurora Kinase A and Cyclin B1 vectors dis-
played normal centrosome-/ spindle formation and chromosome alignment with the 
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regular characteristics as explained for miR neg and pSuper (see Figure 11). No mitotic 
spindle or centrosome defects could be observed.  
 
 
Figure 12: Mitotic cells 72h after nucleofection. Cells are stained with DAPI (blue), gamma 
tubulin (red) and alpha tubulin (green). Abnormalities in spindle assembly analysis are apparent 
e.g. multiple, irregular centrosomes (red) in early prophase; abnormal monopolar spindle 
formation (green) in prophase; abnormal number of centrosomes (red) and abnormal spindle 
formations (green) in prometaphase; multiple centrosomes (red) and mulitpolar spindle formation 
(green) in metaphase. Bar = 20 µm. 
 
On the contrary, in mitotic cells lacking B-Myb, several abnormalities were detected, 
such as multiple centrosomes (red) and abnormal monopolar or multipolar spindle for-
mations (green). There were only very few cells seen in anaphase or telophase.  
 
 
Figure 13: Mitotic spindle formation analysis as percent of mitotic cells. Cells with regular mitotic 
spindle apparatus (blue). Amount of cells with mono- or multipolar spindle formation or an 
irregular configuration of mitotic spindles is displayed as abnormal cells (red). Cells nucleofected 
with pSuper served as negative control. No error bars are given due to aggregate analysis. 
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Figure 14: Centrosome analysis as percent of mitotic cells. Amount of cells containing regular 
bipolar centrosomes (blue), irregular monopolar (red) or mulitpolar centrosomes (green) are 
shown. Cells nucleofected with pSuper served as a negative control. No error bars are given due 
to aggregate analysis. 
 
In summary, a total of 312 cells were analyzed with regard to spindle and centrosome 
formation (see Figure 13, 14) observing that abnormal spindle or centrosome formations 
could only be detected in a small amount of R1 cells lacking Aurora Kinase A or Cyclin 
B1, which was comparable to negative control cells. In contrast, loss of B-Myb led to ir-
regular spindle formations, such as mono- or multipolar spindle apparatus and an 
irregular amount of centrosomes in a significant part of R1 cells. 
 
Furthermore spindle assembly analysis enables the relative amount of cells in the four 
different phases of mitosis to be compared. 
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Figure 15: Phases of mitosis characterized by alpha tubulin and DNA IF staining. Prophase 
includes both prophase and prometaphase.  pSuper and B-Myb shRNA n=2 counts, miR neg, 
Ccnb1 682 and Aurka 702 n=3 counts. * = p value compared to pSuper, # = p value compared to 
miR neg, + = p value compared to Ccnb1 miR, • = p value compared to Aurka. Significance is 
given for within phase only. (i.e. prophase to prophase, not prophase to telophase) 
 
When comparing negative control cells to R1 cells lacking Aurora Kinase A or Cyclin B1, 
there were similar numbers of cells in all stages of mitosis. Whereas B-Myb knockdown 
cells were mostly in prophase and metaphase with only few cells in anaphase and 
telophase (see Figure 15), which can be due to the observed mitotic spindle and centro-
some defects and a resulting delay in mitosis.  
In conclusion, spindle assembly analyses have shown that neither Aurora Kinase A nor 
Cyclin B1 have a significant effect on mitotic progression in embryonic stem cells. The 
phenotype seen by B-Myb knockdown could not be reproduced by knockdown of a 
single target gene. 
 
4.5 Generation of the inducible expression system Line Ainv15 
The genetically modified embryonic stem cells Line Ainv15 contain a reverse tetracycline 
transactivator (rtTA) under control of a CMV (Cytomegalovirus) promoter.  This rtTA is 
inserted at the Rosa26 locus of chromosome 6 to allow a stable and efficient expression. 
The transcribed tetracycline-controlled transactivation proteins bind to the tetracycline 
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responsive element (TRE) at the hprt (hypoxanthine-guanine phosphoribosyltransferase) 
locus of the X-chromosome only in the presence of tetracycline or derivatives such as 
doxycycline. Since binding to the TRE activates transcription of the gene of interest, the 
activation of transgenes can thus be regulated in vivo in a dose-dependent manner. 
Furthermore the ES cells employed comprise the EmGFP (Emerald Green Fluorescent 
Protein) that has been engineered to allow insertion of a miRNA in its 3’UTR. The 
EmGFP sequence contains flanking and loop sequences that facilitate miRNA excision 
and function. An miRNA can thus be expressed co-cistronically with EmGFP, which es-
sentially permits 100 % correlation of EmGFP expression with the knockdown activity of 
miRNA. 
ES cell lines are being generated that can inducibly activate the expression of EmGFP-
containing miRNA to downregulate the specific target.  
 
 
Figure 16: Inducible RNAi in Ainv 15 embryonic stem cells. Schematic illustration of genetically 
modified Ainv 15 cells. 
 
As explained in the aim of this study, it was initially planned to use the inducible expres-
sion system Ainv15 as the last step to get a stronger knockdown and therefore a more 
reliable phenotype compared to knockdown by miRNA. Since my research project was 
limited to six months, I only contributed to the design and preparation of this cell line, but 
was unable to run a detailed analysis in the Ainv15 cells during my stay. This work was 
completed by others after I left the NIA, and the results are not included here at the 
request of my supervisor, Prof. Kenneth Boheler. 
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4.6  Design of a miRNA vector directed against Aurora Kinase A 
To complete the results section, the design of the miRNA vectors directed against 
Aurora Kinase A and Cyclin B1, which provide the basis for my study, is described in 
detail. 
The BLOCK-iT Pol II miR RNAi Expression Vector Kit was chosen for vector-based ex-
pression of miRNA to achieve stable suppression of Aurora Kinase A and Cyclin B1. 
This system was used to clone ds oligos encoding a specific miRNA target sequence 
into a vector containing the human cytomegalovirus (CMV) promoter for use in RNAi 
analysis. The engineered miRNAs produced by this Kit fully complement their target site, 
and thus lead to cleavage of the desired messenger RNA (mRNA).  
The CMV promoter is recognized by RNA Polymerase II and allows a high-level consti-
tutive miRNA expression in mammalian cells. Since the vector includes the EmGFP 
gene, one can visually detect the cells in which knockdown is occurring. The Green 
Fluorescent Protein is a bioluminescent protein derived from the Jellyfish Aequorea 
Victoria and emits fluorescence upon excitation, which can easily be measured by fluo-
rescence microscopy. The Emerald Green Fluorescent Protein is a variant of enhanced 
GFP that increases the intensity of the fluorescence signal.  
By placing the EmGFP gene downstream of the CMV promoter and upstream of the pre-
miR, it can be used as a marker of gene expression, because one can track those cells 
in which the EmGFP protein and miRNA are expressed simultaneously.  
In order to select positive transformants, the vector contains a Spectinomycin and 
Blasticidin resistance gene, which both allow selection in E.coli. Moreover, the 
Blasticidin resistance gene is suitable for selection in mammalian cells to generate 
stable cell lines.  
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Figure 17: Map and Features of the pcDNA 6.2-GW/EmGFP-miR (Invitrogen). 
 
In the first step of the pc DNA 6.2-GW/EmGFP vector construction, the pairs of comple-
mentary DNA oligonucleotides were designed with the help of the BLOCK-iT™ RNAi 
Designer (Invitrogen).  
 
The top-strand oligo encodes the target pre-miRNA and has the following structural 
features: 
- A 5' overhang (TGCT), which is complementary to the vector and required for 
directional cloning (Linker) 
- A 5' G + a short 21 nucleotide antisense sequence (mature miRNA) derived from 
the target gene 
- A short spacer of 19 nucleotides to form a terminal loop 
- A short sense target sequence with 2 nucleotides removed (∆2) to create an inter-
nal loop 
- A 4 nucleotide, 5’ overhang (CAGG) complementary to the vector and required 
for directional cloning (Linker) 
 
 
 
Five pairs of pre-miRNAs were generated for knockdown of Aurora Kinase A: 
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miRNA Aurka 398 
top strand 5'-TGCTGAATCATTTCCGGAGGCTGCAGGTTTTGGCCACTGACTGACCTGCAGCCCGGAAATGATTCAGG-3' 
bottom strand 5'-CCTGAATCATTTCCGGGCTGCAGGTCAGTCAGTGGCCAAAACCTGCAGCCTCCGGAAATGATTC-3' 
ds oligo    5'-TGCTGAATCATTTCCGGAGGCTGCAGGTTTTGGCCACTGACTGACCTGCAGCCCGGAAATGATTCAGG-3' 
3'-CTTAGTAAAGGCCTCCGACGTCCAAAACCGGTGACTGACTGGACGTCGGGCCTTTACTAAGTCC-5' 
 
miRNA Aurka 555 
top strand  5'-TGCTGTTCAGAGCCAGGATGAACTTGGTTTTGGCCACTGACTGACCAAGTTCACTGGCTCTGAACAGG-3' 
bottom strand      5'-CCTGTTCAGAGCCAGTGAACTTGGTCAGTCAGTGGCCAAAACCAAGTTCATCCTGGCTCTGAAC-3' 
ds oligo  5'-TGCTGTTCAGAGCCAGGATGAACTTGGTTTTGGCCACTGACTGACCAAGTTCACTGGCTCTGAACAGG-3' 
             3'-CAAGTCTCGGTCCTACTTGAACCAAAACCGGTGACTGACTGGTTCAAGTGACCGAGACTTGTCC-5' 
 
miRNA Aurka 702 
top strand 5'-TGCTGTCTAGAATCAGATAAACTCGGGTTTTGGCCACTGACTGACCCGAGTTTCTGATTCTAGACAGG-3'  
bottom strand 5'-CCTGTCTAGAATCAGAAACTCGGGTCAGTCAGTGGCCAAAACCCGAGTTTATCTGATTCTAGAC-3'      
ds oligo 5'-TGCTGTCTAGAATCAGATAAACTCGGGTTTTGGCCACTGACTGACCCGAGTTTCTGATTCTAGACAGG-3' 
3'-CAGATCTTAGTCTATTTGAGCCCAAAACCGGTGACTGACTGGGCTCAAAGACTAAGATCTGTCC-5' 
 
miRNA Aurka 1154  
top strand  5'-TGCTGTTGAAATGAGGTCCCTGGCTCGTTTTGGCCACTGACTGACGAGCCAGGCCTCATTTCAACAGG-3' 
bottom strand  5'-CCTGTTGAAATGAGGCCTGGCTCGTCAGTCAGTGGCCAAAACGAGCCAGGGACCTCATTTCAAC-3' 
ds oligo  5'-TGCTGTTGAAATGAGGTCCCTGGCTCGTTTTGGCCACTGACTGACGAGCCAGGCCTCATTTCAACAGG-3'                    
     3'-CAACTTTACTCCAGGGACCGAGCAAAACCGGTGACTGACTGCTCGGTCCGGAGTAAAGTTGTCC-5' 
 
miRNA Aurka 1276 
top strand  5'-TGCTGTTTGCTGGTTGGCTCTTTGCTGTTTTGGCCACTGACTGACAGCAAAGACAACCAGCAAACAGG-3' 
bottom strand  5'-CCTGTTTGCTGGTTGTCTTTGCTGTCAGTCAGTGGCCAAAACAGCAAAGAGCCAACCAGCAAAC-3' 
ds oligo  5'-TGCTGTTTGCTGGTTGGCTCTTTGCTGTTTTGGCCACTGACTGACAGCAAAGACAACCAGCAAACAGG-3' 
3'-CAAACGACCAACCGAGAAACGACAAAACCGGTGACTGACTGTCGTTTCTGTTGGTCGTTTGTCC-5' 
 
The top- and bottom-strand oligonucleotides were annealed, cloned into the linearized 
pc DNA 6.2-GW/EmGFP-miR vector using T4 DNA Ligase and afterwards transformed 
into competent E.coli One Shot TOP10. 50 and 100 μl from each transformation were 
spread on pre-warmed LB agar plates containing 50 μg/ml spectinomycin and incubated 
overnight at 37°C. 10 spectinomycin-resistant colonies were chosen and cultured over-
night in LB medium containing 50 μg/ml spectinomycin. After isolation of the plasmid 
DNA by QuickGene Plasmid kit S II, the correct insertion of the pre-miRNA was con-
firmed by digestion reaction using the restriction enzymes XhoI and SalI (data not 
shown).  
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In order to check the expression of the miRNA, positive transformants were transfected 
into C2C12-cells and fluorescence of the EmGFP protein was detected 24 h later.  
 
 
Figure 18: C2C12 cells transfected with positive transformants. Green fluorescent cells show 
EmGFP expression. Bar = 400 µm. 
 
4.7  Design of a miRNA vector directed against Cyclin B1 
Three pairs of pre-miRNAs were designed with the help of the BLOCK-iT™ RNAi 
Designer (Invitrogen) for knockdown of Cyclin B1. 
 
 
miRNA Ccnb1 682 
top strand 5’-TGCTGTAGCCAGTCAATGAGGATAGCGTTTTGGCCACTGACTGACGCTATCCTTTGACTGGCTACAGG-3’ 
bottom strand    5’-CCTGTAGCCAGTCAAAGGATAGCGTCAGTCAGTGGCCAAAACGCTATCCTCATTGACTGGCTAC-3’ 
ds oligo 
5’-TGCTGTAGCCAGTCAATGAGGATAGCGTTTTGGCCACTGACTGACGCTATCCTTTGACTGGCTACAGG-3’ 
 3’-CATCGGTCAGTTACTCCTATCGCAAAACCGGTGACTGACTGCGATAGGAAACTGACCGATGTCC-5’ 
 
 
miRNA Ccnb1 744 
top strand  5’-TGCTGATAATGGACACAGTCATGTACGTTTTGGCCACTGACTGACGTACATGAGTGTCCATTATCAGG-3’ 
bottom strand 5’-CCTGATAATGGACACTCATGTACGTCAGTCAGTGGCCAAAACGTACATGACTGTGTCCATTATC-3’    
ds oligo 
5’-TGCTGATAATGGACACAGTCATGTACGTTTTGGCCACTGACTGACGTACATGAGTGTCCATTATCAGG-3’ 
          3’-CTATTACCTGTGTCAGTACATGCAAAACCGGTGACTGACTGCATGTACTCACAGGTAATAGTCC-5’ 
 
 
 
miRNA Ccnb1 826 
top strand 5’-TGCTGTTTGCTTGCAATAAACATGGCGTTTTGGCCACTGACTGACGCCATGTTTTGCAAGCAAACAGG-3’ 
bottom strand 5’-CCTGTTTGCTTGCAAAACATGGCGTCAGTCAGTGGCCAAAACGCCATGTTTATTGCAAGCAAAC-3’    
ds oligo 
5’-TGCTGTTTGCTTGCAATAAACATGGCGTTTTGGCCACTGACTGACGCCATGTTTTGCAAGCAAACAGG-3’ 
3’-CAAACGAACGTTATTTGTACCGCAAAACCGGTGACTGACTGCGGTACAAAACGTTCGTTTGTCC-5’ 
 
miR AurK 1276miR AurK 1154miR AurK 702miR Aurk 555miR AurK 398miR neg
52 
 
As mentioned above, the BLOCK-iT Pol II miR RNAi Expression Vector Kit was used for 
vector construction as well. The procedure is identical to that described for the miRNA 
vector directed against Aurora Kinase A (see 4.6). 
 
In order to check the expression of the miRNA, positive transformants were transfected 
into C2C12-cells and fluorescence of the EmGFP protein was detected 24 h later.  
 
 
Figure 19: C2C12 cells transfected with positive transformants. Green fluorescent cells show 
EmGFP expression. Bar = 400 µm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
miR Ccnb1 826miR Ccnb1 744miR Ccnb1 682
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5. Discussion 
Embryonic stem cells and induced pluripotent stem cells have the capacity for unlimited 
self-renewal and the ability to differentiate into all cell types of the three embryonic germ 
layers. Owing to those unique characteristics, ES and iPS cells are considered to serve 
as a possible source for regenerative medicine, including tissue engineering and cell 
replacement therapy.  
The field of regenerative medicine holds great potential to treat injuries and degenerative 
diseases such as heart failure (Cao et al., 2008), diabetes (D'Amour et al., 2006) or 
Parkinson´s disease (Yang et al., 2008). However, before the translation of stem cell 
applications to the clinic can be realized, several problems like e.g. tumor formation 
must be overcome, and a more thorough understanding of the molecular mechanisms 
that form the basis of the pluripotent state of ES and iPS cells is required. In order to 
understand how pluripotency is established and maintained, it is important to determine 
the role of specific transcription factors operating in this regulatory network.  
In this regard, the transcription factor B-Myb was recently spotlighted, because it plays 
an important role in maintaining pluripotency, normal cell cycle progression and chromo-
somal stability of embryonic stem cells. Previous experiments have demonstrated that 
B-Myb is required for proper S phase progression, as B-Myb ablation leads to a signifi-
cant slowdown of the proliferation rate, stalling of replication forks and a superactivation 
of active replication foci causing disorganization of the replication program and an 
increase in double-strand breaks. These defects seen with loss of B-Myb are partly due 
to c-Myc and FOXM1 regulatory mechanisms (Lorvellec et al. 2010). Furthermore 
Tarasov et al. have shown the role of B-Myb in regular progression through G2/M phase, 
since knockdown of B-Myb by shRNA leads to major cell cycle defects and ES cell 
aneuploidy.  
As preliminary ChIP on chip data has indicated, the transcription factor B-Myb regulates 
gene expression of several proteins, which are either cell cycle associated or implicated 
in differentiation. To understand its precise role in cell cycle regulation, it is very 
important to establish whether a generalized reduction of its target genes or 
dysregulation of individual factors causes the phenotype seen by B-Myb knockdown. 
Therefore the function of specific target genes needs to be determined in order to detect 
major or minor contributors of B-Myb. 
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Due to the fact that B-Myb regulates gene expression of Aurora Kinase A and Cyclin B1, 
this project was focused on those target genes to find out if they serve as major or minor 
contributors of B-Myb. 
Aurora Kinase A was chosen because previous experiments in mouse embryonic fibro-
blasts have shown a delayed mitotic entry, defects in spindle formation as well as 
polyploidy relating to Aurora Kinase A ablation (Cowley et al., 2009). That phenotype 
resulting from loss of Aurora Kinase A function in somatic cells is similar to the pheno-
type caused by B-Myb knockdown in embryonic stem cells.  
Since B-Myb regulates gene expression of Aurora Kinase A, this protein could be 
responsible for the observed B-Myb knockdown phenotype. If this hypothesis could be 
proved, the target gene Aurora Kinase A would be a major contributor of B-Myb. 
 
In order to study Aurora Kinase A function in embryonic stem cells, five miRNAs for its 
knockdown were established and tested. With the help of Western Immunoblotting 
miRNA Aurka 702 was chosen, since it achieved lowest protein levels of Aurora Kinase 
A. By contrast, knockdown of B-Myb caused only an insignificant reduction of Aurora 
Kinase A levels, whereas knockdown of Aurora Kinase A by miRNA 702 resulted in a 
relevant decrease in expression at the 72 hours timepoint. 
MiRNA 702 was thus used for cell cycle- and spindle assembly analysis in order to in-
vestigate on the one hand whether the phenotype resulting from Aurora Kinase A 
ablation in somatic cells could be reproduced in ES cells, and on the other hand whether 
reduced expression of Aurora Kinase A is responsible for the phenotype seen by B-Myb 
knockdown and accordingly serves as a major contributor for B-Myb. 
However, cell cycle analysis of R1 cells nucleofected with miRNA Aurka 702 showed a 
regular cell cycle for mES cells containing G1-, S- and G2/M populations with most of 
the cells in S-phase. Neither major cell cycle defects nor polyploid or aneuploid cell 
populations were observed.  
In contrast, cell cycle analysis of B-Myb deficient cells displayed a shift of cells in cell 
cycle with a reduction of cells in G1- and S phases and a significant increase of cells in 
G2/M. That change indicates an increase in cells undergoing abnormal cell division, 
which is confirmed by the observed polyploid population.  
Furthermore, spindle assembly analysis of R1 cells nucleofected with miR Aurka 702 
showed comparable numbers of cells in each stage of mitosis (prophase, metaphase, 
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anaphase, telophase), and no significant amount of abnormally formed spindles when 
compared to miR neg controls. In contrast, Cowley et al. have shown in previous data 
that loss of Aurora Kinase A in mouse embryonic fibroblasts leads to a delayed mitotic 
entry with an accumulation of cells in early prophase as well as defects in bipolar spindle 
formation. This data reveals that the phenotype resulting from Aurora Kinase A ablation 
in somatic cells could not be reproduced in embryonic stem cells with the partial knock-
down in this study. A complete knockdown or knockout of Aurora Kinase A would be ex-
pected to lead to such a phenotype, unless other members of the Aurora Kinase family 
are able to compensate its function. 
The positive control cells (nucleofected with B-Myb shRNA) had very few cells in post-
metaphase phases of the cell cycle and featured several cells with abnormally formed 
spindles such as multiple centrosomes and a spindle apparatus with several central 
points.  
In summary, the data from cell cycle- and spindle assembly analysis clarified that in-
complete knockdown of Aurora Kinase A using miRNA to levels lower than that seen 
with B-Myb knockdown failed to produce the same phenotype. 
 
The target gene Cyclin B1 was chosen for testing because it plays a decisive role in 
promoting several events in early phases of mitosis and due to its decreased expression 
in embryonic stem cells following B-Myb knockdown, the observed mitotic defects have 
been ascribed in part to Cyclin B1 (Boheler, 2009; Tarasov et al., 2008). This assump-
tion is in accordance with preliminary data from megakaryocytes, where transient loss of 
Cyclin B1 causes polyploidy (Zhang et al., 1996).  
To study Cyclin B1 function in mES cells, three miRNAs were established and tested for 
knockdown. Western immunoblotting showed that miRNA 682 was most effective for 
Cyclin B1 knockdown, and accordingly used for further analysis. Levels of Cyclin B1 are 
also decreased both by B-shRNA and by miR Ccnb1 682, but knockdown by miRNA 
leads to lower levels. 
Thus, miRNA 682 was tested in cell cycle and spindle assembly analysis in order to de-
tect whether the phenotype seen by B-Myb knockdown could be reproduced with loss of 
Cyclin B1. If so, the target gene Cyclin B1 would be a major contributor of B-Myb. 
However, cell cycle analysis of R1 cells nucleofected with miRNA Ccnb1 682 showed a 
regular cell cycle for mouse embryonic stem cells. The amount of cells occupying the 
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different phases of cell cycle is in accordance with the typical characteristics of mES 
cells. Contrary to loss of B-Myb, major cell cycle defects such as a delay in a specific 
phase or an additional polyploid or aneuploid cell population were not observed with 
Cyclin B1 knockdown. 
Furthermore, R1 cells nucleofected with miRNA Ccnb1 682 show regular centrosome 
and spindle formation in spindle assembly analysis. In contrast to B-Myb knockdown, 
there was no significant amount of cells containing monopolar/multipolar centrosomes or 
spindle formation defects. In addition, the distribution of cells by phases of mitosis 
equates the negative control. 
Thus, cell cycle and spindle assembly analysis have shown that partial knockdown of 
Cyclin B1 by miRNA in mouse embryonic stem cells does not lead to the same pheno-
type seen with B-Myb knockdown. 
In conclusion, the characteristic aneuploid phenotype observed by loss of B-Myb could 
not be reproduced by a partial knockdown of either Aurora Kinase A or Cyclin B1. Thus, 
the incomplete knockdown of these target genes cannot account for the cell cycle, 
spindle or centrosome defects observed in B-Myb deficient cells. Aurora Kinase A and 
Cyclin B1 may be in fact major contributors of B-Myb, but only in association with other 
essential regulatory factors, such as Plk1, Borealin, INCENP, c-Myc or FOXM1. 
  
There are several different approaches to explain this data.  
1. In the described experiments, miRNAs and shRNAs were used to knockdown 
Aurora Kinase A and Cyclin B1 to levels seen in B-Myb deficient cells in order to 
test whether the observed phenotype following loss of B-Myb can be mimicked. 
Therefore, five miRNAs were designed and tested for Aurora Kinase A knock-
down and three miRNAs for Cyclin B1. The miRNAs Aurka 702 and Ccnb1 682, 
which were used for further analysis, achieved protein levels lower than those 
seen with B-Myb knockdown.  
But nevertheless, knockdown by miRNAs caused decreased protein levels of 
approx. 50 % of Aurora Kinase A and Cyclin B1 compared to negative control, 
whereas use of B-Myb shRNA led to totally reduced protein levels of B-Myb. It 
could be reasonable that lower or totally eliminated protein levels of Aurora 
Kinase A and Cyclin B1 would cause different effects on cell cycle and spindle 
assembly. 
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It is possible to design and test several other miRNAs, and maybe one would be 
found that leads to a more efficient knockdown of Aurora Kinase A or Cyclin B1 
compared to those used in this work. Furthermore, combinations of two or more 
miRNAs could possibly improve the knockdown efficiency as well.  
Another way of achieving a stronger knockdown is through the use of an inducible 
expression system such as the Ainv15 cells, which would permit a more titratable 
and complete response.  
2. Since the transcription factor B-Myb regulates gene expression of many different 
target genes, Aurora Kinase A and Cyclin B1 were picked because of promising 
data from preliminary experiments in differentiated cells, namely mouse embry-
onic fibroblasts (Aurora Kinase A) and megakaryocytes (Cyclin B1).  
By contrast, in embryonic stem cells incomplete knockdown of both B-Myb target 
genes failed to reproduce the phenotype seen in previous experiments in somatic 
cells, i.e. it did not cause aneuploidy or mitotic spindle defects. This contrary data 
could be related to the huge differences between undifferentiated embryonic stem 
cells and somatic cells: ES cells possess three unique molecular properties ‒  a 
unique transcriptional hierarchy, a poised epigenetic state, and a short cell cycle 
transit time (Boheler, 2009). Therefore it is possible that molecular characteristics 
and pathways may vary between those two different types of cells, and specific 
proteins such as the B-Myb target genes Aurora Kinase A or Cyclin B1 function in 
a different way in ES cells than in somatic cells. In this study, it is has been 
shown that partial knockdown of Aurora Kinase A and Cyclin B1, which are 
greatly involved in mitotic regulation in differentiated cells, did not lead to obvious 
cell cycle defects in embryonic stem cells.  
3. Previous experiments in ES cells have shown that knockdown of the transcription 
factor B-Myb by shRNA causes a characteristic phenotype including a delayed 
transit through G2/M, severe mitotic spindle and centrosome defects, and poly-
ploidy (Tarasov et al., 2008). Additionally, knockout of B-Myb results in a 
disturbance of S phase progression with stalling of replication forks and 
superactivation of replication factories (Lorvellec et al.).  Since B-Myb regulates 
gene expression of several genes implicated in cell cycle, it is of great interest to 
detect whether dysregulation of a specific target gene leads to the observed phe-
notype. Although loss of B-Myb results in decreased protein levels of Aurora 
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Kinase A and Cyclin B1, this study has shown that incomplete knockdown of both 
to levels lower than that seen with B-Myb did not cause the specific phenotype.  
In order to find out if dysregulation of another critical B-Myb target gene leads to 
severe cell cycle defects and aneuploidy, other individual factors like Plk1, 
INCENP or Borealin could be tested in an analogous manner. Apart from that, it is 
also possible that the observed B-Myb knockdown phenotype is due to a 
generalized reduction in proteins required for cell cycle progression in embryonic 
stem cells.  
In conclusion, the effects of B-Myb loss on cell cycle progression in ES cells oc-
cur either through deficiency of a critical B-Myb target gene that does not depend 
exclusively on Cyclin B1 or Aurora Kinase A or through a multitude of events 
whose combined dysfunction lead to the cell cycle abnormalities observed fol-
lowing genetic loss or knockdown of B-Myb. 
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6. Summary 
Embryonic stem cells and induced pluripotent stem cells represent a unique cell type 
that features the capacity of unlimited self-renewal and the ability to differentiate into all 
derivatives of the three primary germ layers. ES and iPS cells are therefore a promising 
source for regenerative therapies such as tissue engineering or cell replacement 
therapy. Nevertheless, before widespread stem cell applications in regenerative medi-
cine can be realized, a detailed understanding of the regulatory pathways of pluripotency 
and self-renewal is necessary.  
In this connection, the transcription factor B-Myb plays a decisive role in the regulatory 
network of ES cells and is involved in maintaining pluripotency, normal cell cycle pro-
gression and chromosomal integrity. Since B-Myb regulates gene expression of many 
proteins that are either associated with the cell cycle or implicated in differentiation, the 
question has been raised whether individual target genes act as major contributors of B-
Myb or if the interaction of several proteins fulfills this task. 
Taking previous data in somatic cells into account, the target genes Aurora Kinase A 
and Cyclin B1 were chosen to detect whether they serve as major contributors for B-Myb 
in embryonic stem cells. 
In the present study, miRNAs for knockdown of Aurora Kinase A and Cyclin B1 were 
used for cell cycle and spindle assembly analysis in order to test whether the phenotype 
described for B-Myb knockdown could be reproduced by one of those target genes. 
Contrary to preliminary experiments in somatic cells, incomplete knockdown of neither 
Aurora Kinase A nor Cyclin B1 in ES stem cells led to abnormalities or defects in cell 
cycle or mitotic progression. Partial knockdown of both proteins did not reproduce the 
phenotype caused by B-Myb knockdown. 
The effects of B-Myb in embryonic stem cells must involve multiple factors or another 
critical factor that has to be identified. 
Other B-Myb target genes than Aurora Kinase A or Cyclin B1 can be tested in an analo-
gous manner or by using the Ainv15 cells. Furthermore, dysregulation of several target 
genes could cause the aneuploidy observed with loss of B-Myb. Thus, it is still unclear, 
how B-Myb regulates cell cycle progression precisely in embryonic stem cells. 
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